Population pharmacokinetic modelling of intravenous paracetamol in fit older people displays extensive unexplained variability

Article date: January 2019

By: P. Mian, M. J. Esdonk, K. T. Olkkola, B. C. M. Winter, A. Liukas, I. Spriet, D. Tibboel, M. Petrovic, B. C. P. Koch, K. Allegaert in Volume 85, Issue 1, pages 126-135

Aims

Paracetamol is the analgesic most used by older people. The physiological changes occurring with ageing influence the pharmacokinetics (PK) of paracetamol and its variability. We performed a population PK‐analysis to describe the PK of intravenous (IV) paracetamol in fit older people. Simulations were performed to illustrate target attainment and variability of paracetamol exposure following current dosing regimens (1000 mg every 6 h, every 8 h) using steady‐state concentration (Css‐mean) of 10 mg l–1 as target for effective analgesia.

Methods

A population PK‐analysis, using NONMEM 7.2, was performed based on 601 concentrations of paracetamol from 30 fit older people (median age 77.3 years, range [61.8–88.5], body weight 79 kg [60–107]). All had received an IV paracetamol dose of 1000 mg (over 15 min) after elective knee surgery.

Results

A two‐compartment PK‐model best described the data. Volume of distribution of paracetamol increased exponentially with body weight. Clearance was not influenced by any covariate. Simulations of the standardized dosing regimens resulted in a Css of 9.2 mg l–1 and 7.2 mg l–1, for every 6 h and every 8 h respectively. Variability in paracetamol PK resulted in Css above 5.4 and 4.1 mg l–1, respectively, in 90% of the population and above 15.5 and 11.7, respectively, in 10% at these dosing regimens.

Conclusions

The target concentration was achieved in the average patient with 1000 mg every 6 h, while every 8 h resulted in underdosing for the majority of the population. Furthermore, due to a large (unexplained) interindividual variability in paracetamol PK a relevant proportion of the fit older people remained either under‐ or over exposed.

DOI: 10.1111/bcp.13770

View this article